Efficacy and Safety of Fremanezumab in Patients with Migraine: Real-World Evidence in a Private Neurological Center
DOI:
https://doi.org/10.46531/sinapse/AO/220005/2022Keywords:
Antibodies, Monoclonal, Migraine Disorders/drug therapy, Quality of Life, Sickness Impact Profile, Surveys and QuestionnairesAbstract
Introduction: Migraine is the first cause of disability under 50 years of age. In the last decade there were significant advances in the comprehension of this disorder that led to the development of specific treatments, such as those targeting calcitonin gene-related peptide (CGRP) or its receptor including monoclonal antibodies. Here, we present real life results of a cohort of migraine patients treated with fremanezumab.Material and Methods: We analysed data, collected prospectively for 18 months, of consecutive patients with migraine treated with fremanezumab in a Lisbon center. Patients had a baseline evaluation and monthly visits. Data included monthly headache days, a composite headache measure (days x pain intensity), acute treatment intake and adverse events. Patients also fulfilled quality of life and migraine impact scales at 1st, 3rd, 6th, 9th and 12th months of treatment and were evaluated after treatment withdrawal. Efficacy was defined as a reduction ≥ 30% or ≥ 50% of the number of monthly headache days (in chronic and episodic migraine, respectively) compared to baseline.
Results: We included 29 patients (47.8 years of age, 25 female) with chronic (n=20) or high frequency episodic (n=9), migraine previously resistant to an average of 3.3 oral preventives/botulinum toxin, 20 with medication overuse. Efficacy increased from 62% in the 1st month to 76.9% on the 3rd and there was a significant reduction of migraine headache days, acute medication intake, index and HIT-6 scores and improved quality of life in all assessment periods compared to baseline. The most common adverse events were constipation (27.6%) and pain on the injection site (20.7%) leading to interruption of treatment in one patient. There was no increase in the number of headache days or acute medication intake five months after treatment interruption.
Conclusion: These results corroborate data from clinical trials about the efficacy and safety of fremanezumab, showing an improvement of different migraine measures and impact, even in patients with resistant migraine and medication overuse. In general, adverse events were well tolerated not leading to treatment withdrawal.
Downloads
References
International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1-211. doi: 10.1177/0333102417738202
Steiner T, Stovner L, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020; 21: 137. doi: 10.1186/ s10194-020-01208-0
Steiner T, Stovner L, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J Headache Pain. 2018; 19: 17. doi: 10.1186/s10194-018-0846-2
Steiner T, Stovner L, Katsarava Z, Lainez J, Lampl C, Lantéri-Minet M, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014; 15: 31. doi: 10.1186/1129-2377-15-31
Ramsey R, Ryan J, Hershey A, Powers S, Aylward B, Hommel K. Treatment adherence in patients with headache: a systematic review. Headache. 2014; 54:795-816. doi: 10.1111/head.12353
Edvinsson L, Haanes K, Warfvinge K, Krause D. CGRP as the target of new migraine therapies-successful translation from bench to clinic. Nat Rev Neurol. 2018; 14:338-50. doi: 10.1038/s41582-018-0003-1
Gouveia R, Parreira E. Utilização de Anticorpos Monoclonais no Tratamento da Enxaqueca. A Revolução Terapêutica Há Muito Esperada? Sinapse. 2018; 18: 50-65.
Hoy SM. Fremanezumab: first global approval. Drugs. 2018; 78: 1829-34. Doi: 10.1007/s40265-018-1004-5
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019; 20:6. doi: 10.1186/ s10194-018-0955-y
Constantino M. Adaptação e Validação Intercultural do Headache Impact Test – 6 Item (HIT-6). [Dissertação]. Lisboa: Faculdade de Motricidade Humana da Universidade Técnica de Lisboa; 2005.
Kosinski M, Bayliss M, Bjorner J, Ware Jr, Garber W, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12: 963-74. doi: 10.1023/a:1026119331193
Shin H, Park J, Kim Y, Lee K. Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache Diary. J Clin Neurol. 2008; 4: 158-63. doi: 10.3988/jcn.2008.4.4.158
Yang M, Rendas-Baum R, Varon S, Kosinski M. Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia. 2011; 31: 357-67. doi: 10.1177/0333102410379890
Wagner T, Patrick D, Galer B, Berzon R. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache. 1996; 36: 484-92. doi: 10.1046/j.1526-4610.1996.3608484.x
McKenna S, Doward L, Davey K. The Development and Psychometric Properties of the MSQOL. Clin. Drug Investig. 1998; 15: 413-23. doi: 10.2165/00044011-199815050-00006
European Medicines Agenc. ema.europa.eu. [Internet]. Holanda: EMA; c2021 [cited 2022 mar 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ ajovy
Dodick D, Silberstein S, Bigal M, Yeung P, Goadsby P, Blankenbiller T, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018; 319 (19): 1999-2008. doi: 10.1001/jama.2018.4853
Silberstein S, Dodick D, Bigal M, Yeung P, Goadsby P, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377 : 2113-22. doi: 10.1056/NEJMoa1709038
Ferrari M, Diener H, Ning X, Galic M, Cohen J, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019; 394: 1030–40. doi: 10.1016/s0140-6736(19)31946-4
Tassorelli C, Diener H, Dodick D, Silberstein S, Lipton R, Ashina M, et al. International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018; 38: 815-32. doi: 10.1177/0333102418758283.
Goadsby P, Silberstein S, Yeung P, Cohen J, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020; 95: e2487-99. doi: 10.1212/WNL.0000000000010600
Urits I, Clark G, An D, Wesp B, Zhou R, Amgalan A, et al. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther. 2020; 9: 195-215. doi: 10.1007/s40122-020-00159-3.
infarmed.pt [Internet]. Lisboa: Infarmed; c2016 [cited 2022 mar 28]. Relatório público de avaliação Ajovy (Fremanezumab) Available from: https://www.infarmed.pt/documents/15786/1424140/Relat%C3%B3rio+de+avalia%C3 %A7%C3%A3o+de+financiamento+p%C3%BAblico+de +Ajovy+%28fremanezumab%29+2021/4a164502-6d83-d06e-36f7-dc5035cdfa97
McAllister P, Lamerato L, Krasenbaum L, Cohen J, Tangirala K, Thompson S, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021; 22: 156. doi: 10.1186/s10194-021-01358-9
Barbanti P, Egeo G, Aurilia C, D’Onofrio C, Albanese M, Cetta I, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022; 23:46. doi: 10.1186/s10194-022-01396-x
Robblee J, VanderPluym J. Fremanezumab in the treatment of migraines: evidence to date. J Pain Res. 2019; 12: 2589-95. doi: 10.2147/JPR.S166427
Bartho L, Koczan G, Maggi C. Studies on the mechanism of the contractile action of rat calcitonin gene-related peptide and of capsaicin on the guinea-pig ileum: effect of hCGRP (8-37) and CGRP tachyphylaxis. Neuropeptides. 1993; 25: 325-9. doi: 10.1016/0143-4179(93)90051-b
Torres-Ferrús M, Gallardo V, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021; 268: 3789-98. doi: 10.1007/s00415-021-10523-8
Raffaelli B, Terhart M, Overeem L, Mecklenburg J, Neeb L, Steinicke M, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2022; 42:326-34. doi:1024211046617
Gantenbein A, Agosti R, Gobbi C, Flügel D, Schankin C, Viceic D, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia. 2021; 41: 1181-6. doi: 10.1177/03331024211014616
Terhart M, Mecklenburg J, Neeb L, Overeem L, Siebert A, Steinicke M, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021; 22: 158. doi: 10.1186/ s10194-021-01368-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marli Lopo Vitorino, Isabel Pavão Martins
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
